RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells

International Journal of Oncology

Volumn 28, Issue 1, 2006, Pages 261-269

  Wittrant, Yohann ^a   Lamoureux, François ^a   Mori, Kanji ^a   Riet, Anne ^a   Kamijo, Akira ^b   Heymann, Dominique ^a   Redini, Françoise ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

BMP 2; Bone tumors; Osteosarcoma; RANK; RANKL

Indexed keywords

BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, HUMAN; TNFSF11 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; BIOSYNTHESIS; BONE TUMOR; C3H MOUSE; CELL CULTURE; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LUNG TUMOR; METASTASIS; MOUSE; OSTEOSARCOMA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; CARRIER PROTEINS; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; OSTEOSARCOMA; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 33644793514     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.1.261     Document Type: Article

References (32)

1. Klein ML, Kenan S and Lewis MM: Osteosarcoma: clinical and pathological considerations. Orthop Clin North Am 20: 327-345, 1989.
2. Weiss SW and Goldblum JR: Enzinger and Weiss' Soft Tissue Tumors. 4th edition. Mosby, St. Louis, MO, 2001.
3. Tsuchiya H, Kanazawa Y, Abdel-Wanis ME, et al: Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 20: 3470-3477, 2002.
4. Theoleyre S, Wittrant Y, Kwan Tat S, Fortun Y, Rédini F and Heymann D: The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelling. Cytokine Growth Factor Rev 15: 457-475, 2004.
5. Grimaud E, Soubigou L, Couillaud S, et al: Receptor activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163: 2021-2031, 2003.
6. Huang L, Cheng YY, Chow LTC, Zheng MH and Kumta SM: Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Pathol 55: 877-878, 2002.
7. Thomas RJ, Guise TA, Yin JJ, et al: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458, 1999.
8. Chirgwin JM and Guise TA: Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10: 159-178, 2000.
9. Narita T, Kawakami-Kimura N, Sato M, et al: Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. Oncology 53: 374-381, 1996. (Pubitemid 26283779)
10. Kamijo A, Koshino T, Uesugi M, Nitto H and Saito T: Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett 188: 213-219, 2002.
11. Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D and Rédini F: Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-κB ligand and osteoprotegerin biological activities. Exp Cell Res 293: 292-301, 2004.
12. Chipoy C, Berreur M, Couillaud S, et al: Down-regulation of osteoblast markers and induction of the glial fibrillary acidic protein by Oncostatin M in osteosarcoma cells require PKCδ and STAT3. J Bone Miner Res 19: 1850-1861, 2004.
13. Lee ZH and Kim H-H: Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305: 211-214, 2003.
14. Hay E, Lemonnier J, Fromigue O and Marie PJ : Bone morphogenetic protein-2 promotes osteoblast apoptosis through a smadin-dependent, protein kinase C-dependent signaling pathway. J Biol Chem 276: 29028-29036, 2001.
15. Yoshikawa H, Ohishi M, Kohriki S, Yoshiura M and Ohsaki Y: Establishment and characterisation of an osteoblastic clonal cell line from human mandibular osteosarcoma (HMOS-1). Oral Oncol 33: 163-168, 1997.
16. Ducy P, Zhang R, Geoffroy V, Ridall AL and Karsenty G: Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747-754, 1997.
17. Delaissé J-M, Andersen TL, Engsig MT, Henriksen K, Troen T and Blavier L: Matrix metalloproteinases (MMP) and Cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61: 504-513, 2003.
18. Masuda R, Sakiyama H, Nonaka T, et al: Establishment and characterization of tartrate-resistant acid phosphatase and alkaline phosphatase double positive cell lines. Cell Tissue Res 304: 351-359, 2001.
19. Olstad OK, Gautvik VT, Reppe S, et al: Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning. Anticancer Res 23: 2201-2216, 2003.
20. Miyamoto N, Higuchi Y, Mori K, et al: Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2: 25-38, 2002.
21. Rifas L, Arackal S and Weitzmann MN: Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J Cell Biochem 88: 650-659, 2003.
22. Kafienah W, Bromme D, Buttle DJ, Croucher LJ and Hollander AP: Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem J 331: 727-732, 1998.
23. Littlewood Evans AJ, Bilbe G, Bowler WB, et al: The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57: 5386-5390, 1997.
24. Brubaker KD, Vessella RL, True LD, Thomas R and Corey E: Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18: 222-230, 2003.
25. Croucher PI, Shipman CM, Lippitt J, et al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001.
26. Zhang J, Dai J, Qi Y, et al: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1244, 2001.
27. Michigami T, Ihara-Watanabe M, Yamazaki M and Ozono K: Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61: 1637-1644, 2001.
28. Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999.
29. Tometsko M, Armstrong A, Miller RE, et al: RANK ligand directly induces osteoclastogenic, angiogenic, chemoattractive and invasive factors on RANK-expressing human cancer cells MDA-MB-231 and PC3. J Bone Miner Res 19: S25, 2004.
30. Kawamura C, Kizaki M and Ikeda Y: Bone morphogenetic protein-2 (BMP-2) induces apoptosis in human myeloma cells. Leuk Lymphoma 43: 635-639, 2002.
31. Soda H, Raymond E, Sharma S, et al: Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 9: 327-331, 1998.
32. Wittrant Y, Théoleyre S, Chipoy C, et al: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta Rev Cancer 1704: 49-57, 2004.